How Doyo, How Do You Keep, How Can You Keep?

I think sometimes people focus on these sorts attentions d i think they can be real and meaningful in some cases, but maybe an even bigger one. It's like how an organization itself evolves over time. I've often said that if genetac and roche only discover and develop monoculen animos and small molecules, within a number of decades, we will be an unimportant company. If, on the other hand, we innovate and start to think about arna binding small molecules, or a byve or by specific ana bodies, sel theraby, gen therapy, maybe even bacterial therapies, are going to continue to be important. There's a constant requirement to change